Tevogen Inc.

TVGN
About the company

Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment.

Country: United StatesPrice: $6.00Market Cap: $406.6M

Investment snapshot

0%positive consensus
Scored 1d ago

Positive

0

BUY / PASS

Neutral / negative

2 / 14

NEUTRAL / FAIL

Median fair value

—

No comparable estimates

Models with upside

0 / 17

Positive margin of safety

Key risk

No clean pass — all 16 investors flag at least one profitability criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILNot rankedFAILFAILFAILFAILFAILFAILFAILFAILFAILNEUTRALFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

Annual history · FY 2025 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-31

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-06-30 · TTM ended 2026-06-30

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-31

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-31

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Market data at 2026-11-01

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-31

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · Balance sheet at 2026-06-30

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-31

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Market data at 2026-11-01

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-31

Score computed: 2026-11-14

TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-31

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Where It Passes

    Where It Falls Short

    • Profitability0% pass✓ 1✗ 34▾

      No clean pass — all 16 investors flag at least one profitability criterion

      Positive EPS (10 years)0/6 years positive
      ✗GrahamPositive EPS every year for 10 years
      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Net Income Positive (10+ years)1/6 years positive
      ✗BuffettPositive every year for 10+ years
      ROE (up to 5-year arithmetic mean)
      ✗Buffett> 15% arithmetic mean (app rule)
      Operating Margin (10-yr trend)
      ✗BuffettStable or rising over 10 years
      Free Cash Flow Proxy
      ✗BuffettPositive and growing
      Earnings Variance (10-yr CoV)
      ✗BuffettCoV < 0.3
      Retained Earnings Effectiveness
      ✗Buffett$1 retained -> > $1 market value created
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      ROEN/A (negative equity)
      ✗Lynch> 15%
      EBIT / Enterprise Value-6.4%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-6.4%, ROC=N/A (invested capital <= 0)
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Net Income / Total Assets-599.49%
      ✗PiotroskiROA > 0
      ROA Change YoY-396.55% -> -599.49% (delta: -202.93%)
      ✗PiotroskiCurrent ROA > Prior ROA
      (CFO / Total Assets) vs ROACFO/Assets=-281.28%, ROA=-599.49%
      ✓PiotroskiCFO/Assets > ROA
      Gross Margin Change YoY
      ✗PiotroskiImproved YoY
      Pre-Tax Income / Revenue
      ✗Dreman>= 8%
      Net Income / Shareholders' Equity
      ✗Dreman> 12%
      Margin of Safety
      ✗PabraiP/B < 1.5 or P/E < 15
      Return on Equity
      ✗AkreROE > 20% (3-year avg)
      Discount to Intrinsic Value
      ✗Marks>= 20% below intrinsic value
      Positive Net Income Frequency1/4 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      Operating Income / Revenue
      ✗Ackman>= 15%
      Net Income / Shareholders Equity
      ✗Ackman>= 15%
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Operating Margin Trend
      ✗TempletonNon-negative operating-margin trend over 3 years
      Revenue growth vs. gross and operating margin trend
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      Net income / market capitalization-5.32%; #3900/6340 (top 61.5%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Gross profit / total assets
      ✗AsnessTop 30% of eligible cross-section
      Net income / positive book equity
      ✗AsnessTop 30% of eligible cross-section
      Negative 5-year standard deviation of ROA-3.9619; #5591/5884 (top 95.0%)
      ✗AsnessTop 30% of eligible cross-section
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
      Positive Diluted-EPS Years
      ✗Schloss>= 70% positive over 5-10 observed years (app rule)
    • Valuation0% pass✗ 28▾

      All 13 investors flag TVGN's valuation

      Price / 3-yr avg EPS
      ✗Graham<= 15x
      Price-to-Book Ratio
      ✗Graham<= 1.5x
      P/E x P/B
      ✗Graham<= 22.5
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      EBIT / Enterprise Value-6.4%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-6.4%, ROC=N/A (invested capital <= 0)
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Price / EPS
      ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      Price / Book Value per ShareN/A (negative BVPS)
      ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
      Valuation Reasonableness
      ✗MungerP/E < 25 or Owner Earnings Yield > 5%
      P/E or FCF YieldFCF Yield=-3.0%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      P/B or P/E vs. Historical Average
      ✗MarksP/E < 15 or P/B < 2.0
      Discount to Intrinsic Value
      ✗Marks>= 20% below intrinsic value
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Price vs. Trailing Low133% of trailing low ($4.52)
      ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
      Net income / market capitalization-5.32%; #3900/6340 (top 61.5%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Positive book equity / market capitalization-0.0219; #5403/6449 (top 83.8%)
      ✗AsnessTop 30% of eligible cross-section
      Price / Diluted EPS
      ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
      (EPS CAGR % + Dividend Yield %) / P/E
      ✗Neff> 0.7 (Neff's published traditional edge)
      Price / Tangible Book Value per ShareN/A (non-positive TBVPS)
      ✗SchlossP/TBV <= 1.00x (app cutoff)
      Book Value per Share Change
      ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
      Revenue / market capitalization
      ✗OshaughnessyTop 10% of eligible cross-section
      (Operating cash flow - capex) / market capitalization-3.05%; #2837/4519 (top 62.8%)
      ✗OshaughnessyTop 10% of eligible cross-section
      Trailing six-month price return through the evaluation date-24.15%; #4171/6202 (top 67.3%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Cash Flow0% pass✓ 1✗ 11▾

      No clean pass — all 10 investors flag at least one cash flow criterion

      Free Cash Flow Proxy
      ✗BuffettPositive and growing
      FCF Positive and Growing$-12.4M
      ✗LynchPositive and growing
      Operating Cash Flow$-12.3M
      ✗PiotroskiCFO > 0
      (CFO / Total Assets) vs ROACFO/Assets=-281.28%, ROA=-599.49%
      ✓PiotroskiCFO/Assets > ROA
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      P/E or FCF YieldFCF Yield=-3.0%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      FCF Positive0/2 years FCF positive
      ✗MarksPositive FCF in majority of recent years
      (OCF - CapEx) / Market Cap-51.4%
      ✗Ackman>= 4%
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Positive Operating Cash Flow frequency0/4 years positive
      ✗SleepPositive OCF in >= 70% of available years
      Operating Cash Flow - Capital Expenditures$-12.4M
      ✗Neff> $0 (app proxy for a strong fundamental case)
      (Operating cash flow - capex) / market capitalization-3.05%; #2837/4519 (top 62.8%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Growth0% pass✓ 1✗ 12▾

      No clean pass — all 8 investors flag at least one growth criterion

      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      Inventory Growth vs Revenue GrowthN/A (no inventory)
      ✓LynchInventory growth < Revenue growth
      EPS Growth Direction
      ✗DremanPositive over recent years
      EPS CAGR
      ✗Dreman> 5% annualized
      Positive Net Income Frequency1/4 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      3yr Median Revenue Growth
      ✗Ackman>= 5%
      Positive EPS Growth Frequency
      ✗AckmanPositive EPS growth in >= 3 of last 5 years
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Revenue growth vs. gross and operating margin trend
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      5-year Revenue CAGR
      ✗SleepCAGR > 7%
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
    • Efficiency0% pass✗ 11▾

      All 8 investors flag TVGN's efficiency

      Current Ratio0.33
      ✗Graham>= 2.0
      ROIC (3-5 yr avg)
      ✗Buffett> 10%
      ROIC - WACC
      ✗BuffettPositive (WACC = 10%)
      EBIT / (NWC + Net Fixed Assets)N/A (invested capital <= 0)
      ✗Greenblatt> 25%
      Current Ratio Change YoY0.26 -> 0.22
      ✗PiotroskiIncreased YoY
      Revenue / Total Assets Change YoY
      ✗PiotroskiImproved YoY
      Current Assets / Current Liabilities0.33
      ✗Dreman> 1.5
      Return on Invested CapitalN/A (non-positive invested capital)
      ✗Munger> 15%
      ROIC (high and growing)FY2023: ROIC=unavailable; FY2024: ROIC=unavailable; FY2025: ROIC=unavailable
      ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
      Reinvestment Rate x ROIC
      ✗AkreReinvestment Rate * ROIC > 10%
      ROIC (5-year)
      ✗SleepROIC > 12% in a majority of years
    • Verdicts0% pass✗ 14▾

      Split decision: 14 FAIL · 2 NEUTRAL

      Overall verdict
      ✗GrahamFAIL (0/9)✗BuffettFAIL (0/9)✗LynchFAIL (1/7)•GreenblattNot ranked✗PiotroskiFAIL (F-Score 3)✗DremanFAIL (0/11)✗MungerFAIL (1/4)✗PabraiFAIL (0/3)✗AkreFAIL (0/6)✗MarksFAIL (0/5)✗AckmanFAIL (0/9)✗TempletonFAIL (1/8)✗SleepFAIL (0/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (0/6)✗SchlossFAIL (0/7)•OshaughnessyNEUTRAL (Not ranked)
    • Debt & Leverage8% pass✓ 1✗ 14▾

      11 of 12 flag TVGN's debt & leverage — Graham, Buffett, Lynch +8 more

      LT Debt vs Net Current Assets
      ✗GrahamLT Debt <= Net Current Assets
      Debt/Equity & Interest CoverageD/E: N/A (negative equity), IC: N/A
      ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
      Total Debt / EquityN/A (negative equity)
      ✗Lynch< 0.33
      Cash - Long-term Debt
      ✗LynchPositive preferred
      LT Debt / Total Assets Change0.00% -> 0.00%
      ✓PiotroskiDecreased YoY
      Current Assets / Current Liabilities0.33
      ✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)
      Total Debt / Shareholders' Equity
      ✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00x
      Debt LevelsN/A (non-positive equity)
      ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
      Interest Coverage & Debt/EBITDA
      ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
      Total Debt / Shareholders Equity
      ✗Ackman<= 1.0
      Negative debt-to-equity (higher means less debt)
      ✗AsnessTop 30% of eligible cross-section

    Business & financials

    Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

    Company Profile

    Industry: Pharmaceutical Products
    SIC Sector: Chemicals & Pharmaceuticals
    Size: Small Cap($406.6M)
    Revenue: N/A
    Net Income: $26.3M-91.4% YoY

    Financial Snapshot

    Operating Margin--
    Return on Equity319.1%
    Debt / Equity-0.20
    Current Ratio0.22
    EPS (Diluted)$-8.08

    Company Financials

    Latest TTM and quarters alongside annual years

    TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

    The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

    MetricTTM · 2026-06-30

    2025-07-01 – 2026-06-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, net income, operating income, ebit.

    Q2 FY 2026

    2026-04-01 – 2026-06-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow.

    Q1 FY 2026

    2026-01-01 – 2026-03-31

    Sources
    FY 2025
    Sources
    • 10-K · 2026-03-31
    FY 2024
    Sources
    • 10-K · 2025-04-02
    FY 2023
    Sources
    • 10-K · 2024-04-29
    FY 2022
    Sources
    • 10-K · 2024-04-29
    FY 2021
    Sources
    • 10-K · 2022-04-01
    Market Cap$406.6Mcurrent----$1.2Mest.$265.2Mest.$6.5Best.----
    Revenue----------------
    Operating Income-$21.4M↑32%-$5.7M↓4%-$5.4M↑48%-$26.1M↑51%-$53.6M↓506%-$8.8M----
    Net Income-$21.6M↑31%-$5.8M↓5%-$5.4M↑47%-$26.3M↓91%-$13.7M↑77%-$60.5M↓1472%$4.4M--
    EPS (Diluted)--$-1.52↓4967%$-1.61↓2200%$-8.08↓11443%$-0.07↑97%$-2.44----
    Gross Margin————————
    Operating Margin————————
    ROE243.1%↓26%——319.1%↑55%205.7%↑221%64.0%↑593%-13.0%—
    Total Debt$1.7M$1.7M$1.7M$1.7M$1.7M↑1%$1.6M$0--
    Shareholders' Equity-$8.9M↑6%-$8.9M↑6%-$9.8M↓27%-$8.2M↓23%-$6.7M↑93%-$94.4M↓178%-$34.0M↓139%-$14.2M
    Current Ratio0.33↑28%0.33↑28%0.29↓17%0.22↓17%0.26↑1195%0.02↓97%0.78↓94%13.33
    Debt / Equity-0.19↓7%-0.19↓7%-0.17↑22%-0.20↑19%-0.25↓1332%-0.020.00—
    Operating Cash Flow-$11.6M↑13%-$3.0M↑6%-$2.7M↑17%-$12.3M↓3%-$12.0M↓47%-$8.2M↓3694%-$215.4K--
    Free Cash Flow-------$12.4M---$8.3M----

    Score history

    Historical Score Timeline

    Industry peers

    Industry Peers

    Similar companies in Pharmaceutical Products

    TVGN vs Peers — Financial Grading

    RevenueN/A
    Net Income$26.3MBottom 25%
    ROE319.1%Top 25%
    D/E-0.20Top 25%
    Op. Margin—
    Curr. Ratio0.22Bottom 25%
    CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
    Merck & Co., Inc.MRK$364.3B$147.76$65.0B$18.3B34.7%0.94—1.542/95/94/70/3F-Score 41/11
    ABBOTT LABORATORIESABT$188.0B$108.52$44.3B$6.5B12.5%0.2518.2%1.583/94/92/71/3F-Score 53/11
    BRISTOL MYERS SQUIBB COBMY$129.7B$63.43$48.2B$7.1B38.2%2.4419.4%1.262/91/93/71/3F-Score 85/11
    BIO-TECHNE CorpTECH$11.4B$72.80$1.2B$73.4M3.8%—8.4%3.464/93/93/70/3F-Score 54/11
    REPLIGEN CORPRGEN$10.7B$167.79$738.3M$48.9M2.3%0.267.5%8.373/92/93/70/3F-Score 75/11
    IONIS PHARMACEUTICALS INCIONS$4.8B$29.06$943.7M$381.4M-78.0%3.60-40.4%3.833/91/91/70/3F-Score 43/11
    NEOGEN CORPNEOG$2.5B$11.23$870.4M$7.9M-0.4%0.76-2.5%3.823/91/92/70/3F-Score 64/11
    Pharvaris N.V.PHVS$2.4B$33.36—$206.4M-64.8%0.00——0/90/92/70/3F-Score 22/11